Abstract

Introduction/objective There are no data on the comparative efficacy of venlafaxine to other SSRI's in severe MDD. Methods In a post hoc analysis, data were pooled from 8 double-blind active controlled studies in outpatients with a diagnosis of MDD. Patients randomly assigned to venlafaxine (dose range 75-225 mg) or SSRI (fluoxetine (20–80 mg/day), fluvoxamine (100 mg/day), or paroxetine (20 mg/day)) were included in the analysis. Severe MDD was defined as baseline HAM-D 17 >24 and alternatively as baseline MADRS≥ 31. Treatment groups were compared by mean improvement in the 17-item Hamilton Rating Scale for Depression (HAM-D 17 ) (and alternatively MADRS) scores from baseline to last observation carried forward (LOCF). Secondary outcomes included HAM-D 17 response (≥50% reduction in HAM-D 17 ) and remission (HAM-D 17 ≤7) rates, MADRS response (≥50% reduction in MADRS) and remission (MADRS≤10). Changes from baseline for the primary end point were evaluated using analysis of covariance with treatment, study, and baseline in the model. Results A total of 1503 patients were included in the analysis (venlafaxine n = 805; SSRI, n = 698); 649/1503 (43%) patients had severe depression (HAM-D 17 >24) at baseline. Venlafaxine improved HAM-D 17 scores vs. SSRI in patients with severe MDD (venlafaxine, −15.26 [0.73]; SSRI, −12.91 [0.81]; P = 0.003). Response and remission were significantly higher in venlafaxine compared with SSRI (Response: Venlafaxine = 63% vs SSRI= 53% (p = 0.004); Remission: 41% vs. 31% (p = 0.005)). The results of the analyses were similar when baseline severity was defined by MADRS scores. Conclusions In this retrospective pooled analysis, venlafaxine was superior to SSRI's in treating severe MDD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call